CRVS
CorvusDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The long case is that soquelitinib is gaining credibility across both immune disease and PTCL, with positive cohort-4 atopic dermatitis data, a newly initiated Phase 2 AD study, an ongoing registrational Phase 3 PTCL program, and runway into the second quarter of 2028 after the January financing [#PR-2026-01-20] [#PR-2026-03-12] [#10-K-2026-03-12].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.6.
What can break
Peer set is loose and forward visibility is still mostly milestone-monitoring rather than revenue-backed.
Momentum
10
Value
41
Sentiment
83
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $16.00 · Bull $23.00 · Bear $9.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $35.00
Why
Momentum10 · Δ7d -8.6
Value41 · Δ7d +0.1
Sentiment83 · Δ7d +9.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
10
34% active weight
Current posture
7d trendSoftening
Δ7d
-8.6
Δ21d
-76.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
83
33% active weight
Current posture
7d trendImproving
Δ7d
+9.6
Δ21d
+39.6
Why this grade
Composite grade D. Momentum 10.1 / Value 41.1 / Sentiment 83.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$1.02B
Beta
0.70
Shares Out
74.68M
P/E (TTM) · Derived
-13.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-32.10
Rev YoY
-
EPS YoY
+79.7%
Gross Margin
-
Op Margin
-
Net Debt
-$51.96M
Current Ratio
8.29
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology